Pharmacological WEE1 inhibition as a strategy to overcome cisplatin resistance in non-seminoma testicular cancer: insights from preclinical models | Synapse
March 3, 2026Open Access
Pharmacological WEE1 inhibition as a strategy to overcome cisplatin resistance in non-seminoma testicular cancer: insights from preclinical models
Key Points
Cisplatin resistance is a major challenge in treating non-seminoma testicular cancer.
WEE1 inhibition significantly enhances the effectiveness of cisplatin in preclinical models.
This study utilizes various preclinical models to analyze the effects of WEE1 inhibitors on cancer cells.
The findings support the potential for new therapeutic strategies to improve treatment outcomes in patients.